Literature DB >> 25879470

In-silico prediction of drug targets, biological activities, signal pathways and regulating networks of dioscin based on bioinformatics.

Lianhong Yin1, Lingli Zheng2, Lina Xu3, Deshi Dong4, Xu Han5, Yan Qi6, Yanyan Zhao7, Youwei Xu8, Jinyong Peng9,10.   

Abstract

BACKGROUND: Inverse docking technology has been a trend of drug discovery, and bioinformatics approaches have been used to predict target proteins, biological activities, signal pathways and molecular regulating networks affected by drugs for further pharmacodynamic and mechanism studies.
METHODS: In the present paper, inverse docking technology was applied to screen potential targets from potential drug target database (PDTD). Then, the corresponding gene information of the obtained drug-targets was applied to predict the related biological activities, signal pathways and processes networks of the compound by using MetaCore platform. After that, some most relevant regulating networks were considered, which included the nodes and relevant pathways of dioscin.
RESULTS: 71 potential targets of dioscin from humans, 7 from rats and 8 from mice were screened, and the prediction results showed that the most likely targets of dioscin were cyclin A2, calmodulin, hemoglobin subunit beta, DNA topoisomerase I, DNA polymerase lambda, nitric oxide synthase and UDP-N-acetylhexosamine pyrophosphorylase, etc. Many diseases including experimental autoimmune encephalomyelitis of human, temporal lobe epilepsy of rat and ankylosing spondylitis of mouse, may be inhibited by dioscin through regulating immune response alternative complement pathway, G-protein signaling RhoB regulation pathway and immune response antiviral actions of interferons, etc. The most relevant networks (5 from human, 3 from rat and 5 from mouse) indicated that dioscin may be a TOP1 inhibitor, which can treat cancer though the cell cycle- transition and termination of DNA replication pathway. Dioscin can down regulate EGFR and EGF to inhibit cancer, and also has anti-inflammation activity by regulating JNK signaling pathway.
CONCLUSIONS: The predictions of the possible targets, biological activities, signal pathways and relevant regulating networks of dioscin provide valuable information to guide further investigation of dioscin on pharmacodynamics and molecular mechanisms, which also suggests a practical and effective method for studies on the mechanism of other chemicals.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25879470      PMCID: PMC4354738          DOI: 10.1186/s12906-015-0579-6

Source DB:  PubMed          Journal:  BMC Complement Altern Med        ISSN: 1472-6882            Impact factor:   3.659


Background

Bioinformatics uses statistics and computer science to process heterogeneous biological data, which provides opportunities for understanding disease genetics, biological processes and identifying therapeutic targets [1]. During the last decades, drug discoveries have tuned into the combination of experimental approaches and modern science of computational. Various tools and techniques have been used for target identification, enrichment analysis and network algorithm. To date, several in silico bioinformatic methods have been developed and applied [2,3]. Drug targets have been predicted by using chemical two-dimensional structural similarity approach and Bipartite graph learning method [4], in which inverse-docking approach plays an important role in target identification [5,6]. Inverse docking is a novel technology that can dock a compound with known biological activity into the binding sites of all 3D structures in given protein database [7]. The procedure of docking involves multiple conformer shape-matching alignment of drug molecule to a cavity followed by molecular-mechanics torsion optimization and energy minimization on both the molecule and the protein residues at the binding region [8]. And the screening is conducted by the evaluation of molecular mechanics energy, and the potential protein ‘hits’ can be selected by further analysis of binding competitiveness against other ligands that bind to the same receptor site [9]. Further, the most commonly used drug target database is potential drug target database (PDTD, http://www.dddc.ac.cn/pdtd/), which it contains 1207 entries covering 841 known and potential drug targets with structures from the Protein Data Bank (PDB) [10]. There are also a number of academic or commercial available pathway databases and network building tools, such as MetaCore™ and Integrity SM [11,12]. MetaCore™ is one of the most suitable tools for functional mining of large, inherently noisy experimental datasets, and the network visualization of drug-target, target disease and disease-gene associations can provide useful information for studies of therapeutic indications and adverse effects of drugs [13,14]. Traditional Chinese medicines (TCMs) have been used to treat many diseases for thousands of years. Dioscin, a natural steroidal saponin, exists in many Chinese medical herbs including Dioscorea nipponica Makino, Dioscorea zingiberensis C. H. Wright and Dioscorea futschauensis Uline. Pharmarcological studies have showed that dioscin has anti-tumor, anti-hyperlipidemic, anti-fungal and anti-virus activities [15-18]. And our previous studies showed that dioscin has significant hepatoprotective effects on carbon tetrachloride (CCl4) and acetaminophen induced liver damage in mice [19-21]. In the future, more and more researches of dioscin will be investigated because of its important medical value. How will the studies be defined in terms of targets priorities, biological activities, signal pathways and regulating networks affected by the compound? In routine works, the experiments with a lot of blindness should be carried out step-by-step [22,23], and they will last a long time with time consuming and laborious. Thus, a prediction of the drug targets, biological activity, signal pathways and regulatory pathways is necessary, and it will provide complementary and supporting evidence for the next experiments studies. In the present paper, the drug-targets were predicted based on inverse docking, and enrichment analysis and network assays of dioscin were carried out by GeneGo’s MetaCore™ techniques. Some possible targets, biological activities, signal pathways and regulating networks of dioscin were predicted in advance, which should provide useful information for further investigation.

Methods

System

In the present paper, 2D chemical structure of dioscin was sketched using MarvinSketch (http://www.chemaxon.com), and three-dimension (3D) structure of dioscin was constructed using ISIS/Draw (ISIS/Draw, MDL Information Systems, Inc., San Leandro, CA, USA). Then, the identification and validation of all potential targets of dioscin were carried out by MDock software. The MDock is automated molecular docking software for simultaneously docking dioscin with known/available three-dimension crystal structure against drug targets from PDTD with multiple protein structure/conformations downloaded from RCSB Protein Data Bank (PDB) by using the ensemble docking algorithm [24]. After that, MetaCore platform was used to analysis the biological activities, signal pathways and regulating networks, which is a suite of software oriented toward understanding the function of gene sets discovered by expression analysis (Table 1) and based on a proprietary manually curated database of protein-protein, and protein-DNA interactions, metabolic and signaling pathways. The analysis process of the prediction of drug targets, biological activities, signal pathway and regulating networks is shown in Figure 1.
Table 1

Tools and databases of MetaCore platform

Software/Databases Website Description
MetaCore database http://lsresearch.thomsonreuters.com/ A manually curated interactions database for >90% human protein with known function.
Gene Ontology http://www.geneontology.org The most often referred to publicly available protein classification based on cellular processed developed by Gene Ontology Consortium.
MetaCore, pathway module http://lsresearch.thomsonreuters.com/maps/ A part of commercial tool MetaCore, the pathways module contains 350 interactive maps for > 2000 established pathways in human signaling, regulation and metabolism. High throughput data can be superimposed on the maps and networks built for any object.
MetaCore http://lsresearch.thomsonreuters.com/ An integrated analytical suite based on a manually curated data of human protein-protein and protein-DNA interactions. All type of high throughput data can be used for building networks.
Figure 1

The analysis process of the prediction of drug targets, biological activities, signal pathway and regulating networks.

Tools and databases of MetaCore platform The analysis process of the prediction of drug targets, biological activities, signal pathway and regulating networks.

Target protein screening

In the procedure of screening targets, the chemical structure of dioscin was sketched to three-dimension structure by ISIS/Draw for identifying potential biological targets. Then, the structure file was uploaded to the MDock software, the binding site analysis was applied with PDTD. In the procedure, the binding site analysis enable to identify and characterize a protein’s binding site, then use those characteristics to look for similar features in other proteins. The active site and binding energy (kcal/mol) of them were defined and calculated, when the potential drug target proteins were founded. And the threshold value of predicted binding energy was–50.0 and other options used default settings to screen the high binding target protein.

Gene ontology analysis

Enrichment analysis

The corresponding gene of screened target proteins were uploaded to MetaCore platform, and the functional analyses of related data were worked out by ontology enrichment analysis based gene ontology. Here, the category of GeneGo biological processes were chosen, which includes some prebuilt molecular interaction networks, including protein-protein and protein-compounds metabolites, protein-nucleic acid interactions between all the networks. At first, the data should be activated. When analyzing data, make sure that the threshold is set appropriately. In the analysis settings, the fold change threshold was set at 0.001, and the p-value threshold was 0.05. Namely, any genes with fold change values less than 0.001 were filtered out. Meanwhile, p-value threshold filters out genes with a p-value of more than 0.05. Other parameters also were set before analysis, such as signals was set as both, sorting method was set as statistically significant. The enrichment analysis consists of matching gene IDs of possible targets for the “common”, “similar” and “unique” sets with gene IDs in functional ontologies in MetaCore. The probability of a random intersection between a set of IDs of the size of listed targets with ontology entities is estimated in p-value of hypergeometric intersection. The lower p-value means higher relevance of the entity to the dataset, which shows in higher rating for the entity. The ontologies include GeneGo Pathway Maps, GeneGo process Networks, Go Processes and GeneGo Diseases (by Biomarkers). The degree of relevance to different categories for the uploaded datasets is defined by p-values, and so the lower p-value gets higher priority. The distributions are calculated and showed as histograms of 10 most significant results (ranked by the-log (p-value)).

Most relevant networks analysis

The gene of the uploaded files is used as the input list for gene statistics analysis, the correlation between gene and network objects were obtained, and the intensity corresponds to the expression values were provided. Then, the obtained results were used for network statistics based networks built from active experiments, the relevant network objects of each network were listed, including the divergence hubs convergence hubs, edges in and edges out. The generation of biological networks uses Analyze Networks (AN) algorithm with default settings. This is a variant of the shortest paths algorithm with main parameters of relative enrichment with the uploaded data, and relative saturation of networks with canonical pathways. These networks are built on the fly and unique for the uploaded data. In this workflow the networks are prioritized based on the number of fragments of canonical pathways on the network.

Results and discussion

Target proteins

Inverse docking was used to identify new potential biological targets, or to identify target for components among a family of related receptors. In the present paper, 71 potential targets of dioscin identified from humans’ proteins, 7 from rats and 8 from mice were screened by MDock software. These target proteins belong to enzymes, G-protein-coupled, receptors, ion channels, and nuclear receptors, which are listed in Table 2.
Table 2

The target proteins of dioscin from human, rat and mouse searched in PDTD

No PDB Uniprot_id Gene symbol Protein name Gene id Energy
Human
12old--Immune system-−64.3
21iyhPTGD2_HUMANPTGDS2Glutathione-requiring prostaglandin D synthase27306−65.2
31uduPDE5A_HUMANPDE5AcGMP-specific 3′,5′-cyclic phosphodiesterase8654−58
42ax4PAPS2_HUMANPAPSS2Bifunctional 3′-phosphoadenosine 5′-phosphosulfate synthetase 29060−73.8
51ivoEGFR_HUMANEGFREpidermal growth factor receptor [Precursor]1956−67.4
62a73CO3_HUMANC3Complement C3 [Precursor]718−67.6
71ivoEGF_HUMANEGFPro-epidermal growth factor [Precursor]1950−67.4
81xbtKITH_HUMANTK1Thymidine kinase, cytosolic7083−71
91w4rKITH_HUMANTK1Thymidine kinase, cytosolic7083−70.2
101l5qPYGL_HUMANPYGLGlycogen phosphorylase, liver form5836−68.8
111pl2GSTA1_HUMANGSTA1Glutathione S-transferase A12938−65.1
121m5oSNRPA_HUMANSNRPAU1 small nuclear ribonucleoprotein A6626−74
131tl8TOP1_HUMANTOP1DNA topoisomerase 17150−55.2
141rr8TOP1_HUMANTOP1DNA topoisomerase 17150−62.1
151nd6PPAP_HUMANACPPProstatic acid phosphatase [Precursor]55−57.7
162c5nCCNA2_HUMANCCNA2Cyclin-A2890−72.2
172c6tCCNA2_HUMANCCNA2Cyclin-A2890−67.4
182c5xCCNA2_HUMANCCNA2Cyclin-A2890−73.8
191yahEST1_HUMANCES1Liver carboxylesterase 1 [Precursor]1066−68.3
202c5nCDK2_HUMANCDK2Cell division protein kinase 21017−72.2
212c6tCDK2_HUMANCDK2Cell division protein kinase 21017−67.4
222c5xCDK2_HUMANCDK2Cell division protein kinase 21017−73.8
231sk6CYAA_BACANcyaCalmodulin-sensitive adenylate cyclase [Precursor]2820138−63.3
241sk6CYAA_BACANcyaCalmodulin-sensitive adenylate cyclase [Precursor]3361726−63.3
252a4zPK3CG_HUMANPIK3CGPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform5294−61.2
261sa4FNTA_HUMANFNTAProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha2339−63.5
271sa4FNTB_HUMANFNTBProtein farnesyltransferase subunit beta2342−63.5
281h2vNCBP2_HUMANNCBP2Nuclear cap-binding protein subunit 222916−61.2
292uymKIF11_HUMANKIF11Kinesin-like protein KIF113832−58.8
301ko6NUP98_HUMANNUP98Nuclear pore complex protein Nup98-Nup96 [Precursor]4928−74.2
312i6aADK_HUMANADKAdenosine kinase132−66.6
322fdpBACE1_HUMANBACE1Beta-secretase 1 [Precursor]23621−70.2
332ic5RAC3_HUMANRAC3Ras-related C3 botulinum toxin substrate 3 [Precursor]5881−75.3
341sk6CALM_HUMANCALM1Calmodulin801−63.3
351sk6CALM_HUMANCALM1Calmodulin808−63.3
361sk6CALM_HUMANCALM1Calmodulin805−63.3
371 m63PPIA_HUMANPPIAPeptidyl-prolyl cis-trans isomerase A5478−81.3
381 m63PPIA_HUMANPPIAPeptidyl-prolyl cis-trans isomerase A653214−81.3
391 m63PPIA_HUMANPPIAPeptidyl-prolyl cis-trans isomerase A654188−81.3
401 m63CANB1_HUMANPPP3R1Calcineurin subunit B type 15534−81.3
411y4vHBB_HUMANHBBHemoglobin subunit beta3043−79.9
421y4gHBB_HUMANHBBHemoglobin subunit beta3043−62.1
431y45HBB_HUMANHBBHemoglobin subunit beta3043−57.1
441y85HBB_HUMANHBBHemoglobin subunit beta3043−55.6
451rq3HBB_HUMANHBBHemoglobin subunit beta3043−63
461y46HBB_HUMANHBBHemoglobin subunit beta3043−59.4
471y7gHBB_HUMANHBBHemoglobin subunit beta3043−71.9
481y4qHBB_HUMANHBBHemoglobin subunit beta3043−73.6
491y4vHBA_HUMANHBA1Hemoglobin subunit alpha3039−79.9
501y4vHBA_HUMANHBA1Hemoglobin subunit alpha3040−79.9
511y4gHBA_HUMANHBA1Hemoglobin subunit alpha3040−62.1
521y4gHBA_HUMANHBA1Hemoglobin subunit alpha3039−62.1
531y45HBA_HUMANHBA1Hemoglobin subunit alpha3040−57.1
541y45HBA_HUMANHBA1Hemoglobin subunit alpha3039−57.1
551y85HBA_HUMANHBA1Hemoglobin subunit alpha3040−55.6
561y85HBA_HUMANHBA1Hemoglobin subunit alpha3039−55.6
571rq3HBA_HUMANHBA1Hemoglobin subunit alpha3040−63
581rq3HBA_HUMANHBA1Hemoglobin subunit alpha3039−63
591y46HBA_HUMANHBA1Hemoglobin subunit alpha3040−59.4
601y46HBA_HUMANHBA1Hemoglobin subunit alpha3039−59.4
611y7gHBA_HUMANHBA1Hemoglobin subunit alpha3040−71.9
621y7gHBA_HUMANHBA1Hemoglobin subunit alpha3039−71.9
631y4qHBA_HUMANHBA1Hemoglobin subunit alpha3040−73.6
641y4qHBA_HUMANHBA1Hemoglobin subunit alpha3039−73.6
651froLGUL_HUMANGLO1Lactoylglutathione lyase2739−67.4
661 m63PP2BA_HUMANPPP3CASerine/threonine-protein phosphatase 2B catalytic subunit alpha isoform5530−81.3
671h2vNCBP1_HUMANNCBP1Nuclear cap-binding protein subunit 14686−61.2
682gk6RENT1_HUMANUPF1Regulator of nonsense transcripts 15976−72.9
692ovpFBXW7_HUMANFBXW7F-box/WD repeat-containing protein 755294−63.5
702pfoDPOLL_HUMANPOLLDNA polymerase lambda27343−60.7
712 h16ARL5A_HUMANARL5AADP-ribosylation factor-like protein 5A26225−66.6
Rat
11cteCATB_RATCtsbCathepsin B [Precursor]-−65.8
21ewkGRM1_RATGrm1Metabotropic glutamate receptor 1 [Precursor]24414−68.6
31zzuNOS1_RATNos1Nitric oxide synthase, brain24598−74.3
41rs6NOS1_RATNos1Nitric oxide synthase, brain24598−76.2
51kzoFNTB_RATFntbProtein farnesyltransferase subunit beta64511−67.4
62bedFNTB_RATFntbProtein farnesyltransferase subunit beta64511−71.5
71kzoFNTA_RATFntaProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha25318−67.4
Mouse
12ihmDPOLM_MOUSEPolmDNA polymerase mu54125−59.2
21f3aGSTA1_MOUSEGsta1Glutathione S-transferase A114857−63
32oi9HA1L_MOUSEH2-LH-2 class I histocompatibility antigen, L-D alpha chain [Precursor]-−62.1
41ieaHA21_MOUSEH2-EaH-2 class II histocompatibility antigen, E-D alpha chain [Precursor]-−66.5
51fngHA22_MOUSE-H-2 class II histocompatibility antigen, E-K alpha chain [Precursor]-−66.1
61qomNOS2_MOUSENos2Nitric oxide synthase, inducible18126−66.2
72gb4TPMT_MOUSETpmtThiopurine S-methyltransferase22017−57.5
82oi9TVA1_MOUSE-T-cell receptor alpha chain V region PHDS58 [Precursor]
The target proteins of dioscin from human, rat and mouse searched in PDTD

Enrichment analysis

GeneGo pathway Maps

It is generally recognized that the pathway-based analysis can provide much significant information. Canonical pathway maps represent a set of about 650 signaling and metabolic maps covering human biology (signaling and metabolism) in a comprehensive way. The profile of network objects (Table 3) was uploaded to search canonical pathway maps. All maps are drawn from scratch by GeneGo annotators and manually curated & edited. From the distributions shown in Figure 2, the most significantly multistep pathways from literature consensus were enriched in the data set. Experimental data is visualized on the maps as yellow (for down-regulation) histograms. The height of the histogram corresponds to the relative expression value for a particular gene/protein.
Table 3

The Network objects and its functions

No Species Gene Name Network Objects Protein Function
1Homo sapiensACPPPPAPProtein phosphatase
2Homo sapiensADKAdenosine kinaseGeneric kinase
3Homo sapiensARL5AARL5RAS superfamily
4Homo sapiensBACE1BACE1Generic protease
5Homo sapiensC3C3Generic binding protein
C3aGeneric binding protein
C3bGeneric binding protein
C3cGeneric binding protein
C3dgGeneric binding protein
C5 convertase (C2aC4bC3b)Generic protease
C5 convertase (C3bBb)Generic protease
iC3bGeneric binding protein
6Homo sapiensCALM1CalmodulinGeneric binding protein
7Homo sapiensCALM2CalmodulinGeneric binding protein
8Homo sapiensCALM3CalmodulinGeneric binding protein
9Homo sapiensCCNA2Cyclin AGeneric binding protein
Cyclin A2Generic binding protein
10Homo sapiensCDK2CDK2Protein kinase
11Homo sapiensCES1CES1Generic enzyme
12Homo sapiensEGFEGFReceptor ligand
13Homo sapiensEGFREGFRReceptor with enzyme activity
14Homo sapiensFBXW7Cul1/Rbx1 E3 ligaseGeneric enzyme
FBXW7Generic binding protein
Skp2/TrCP/FBXWGeneric binding protein
15Homo sapiensFNTAFTaseGeneric enzyme
FTase-alphaGeneric enzyme
GGTase-IGeneric enzyme
16Homo sapiensFNTBFTaseGeneric enzyme
FTase-betaGeneric enzyme
17Homo sapiensGLO1Glyoxalase IGeneric enzyme
18Homo sapiensGSTA1GSTA1Generic enzyme
19Homo sapiensHBA1Adult hemoglobinGeneric protein
Alpha1-globinTransporter
HP/HB complexGeneric protein
20Homo sapiensHBA2Adult hemoglobinGeneric protein
Alpha1-globinTransporter
HP/HB complexGeneric protein
21Homo sapiensHBBAdult hemoglobinGeneric protein
HBBTransporter
HP/HB complexGeneric protein
22Homo sapiensHPGDSPGDSGeneric enzyme
23Homo sapiensKIF11KNSL1Generic binding protein
24Homo sapiensNCBP1CBP80Generic binding protein
25Homo sapiensNCBP2CBP20Generic binding protein
26Homo sapiensNUP98NUP98Generic channel
NUP98/HHEX fusion proteinTranscription factor
NUP98/HOXA9 fusion proteinTranscription factor
Nuclear pore complex proteinsGeneric channel
27Homo sapiensPAPSS2PAPSS2Generic kinase
28Homo sapiensPDE5APDEGeneric protein
PDE5AGeneric enzyme
29Homo sapiensPIK3CGPI3K cat class IB (p110-gamma)Lipid kinase
30Homo sapiensPOLLDNA polymerase lambdaGeneric enzyme
31Homo sapiensPPIACyclophilin AGeneric enzyme
32Homo sapiensPPP3CACalcineurin A (alpha)Protein phosphatase
Calcineurin A (catalytic)Protein phosphatase
33Homo sapiensPPP3R1Calcineurin B (regulatory)Generic binding protein
Calcineurin B1Generic binding protein
34Homo sapiensPYGLGlycogen phosphorylaseGeneric enzyme
PYGLGeneric enzyme
35Homo sapiensRAC3Rac3RAS superfamily
36Homo sapiensSNRPASNRPAGeneric binding protein
37Homo sapiensTK1TK1Generic kinase
38Homo sapiensTOP1TOP1Generic enzyme
39Homo sapiensUPF1RENT1Generic binding protein
1Rattus norvegicusCtsbCathepsin BGeneric protease
2Rattus norvegicusFntaFTaseGeneric enzyme
FTase-alphaGeneric enzyme
GGTase-IGeneric enzyme
3Rattus norvegicusFntbFTaseGeneric enzyme
FTase-betaGeneric enzyme
4Rattus norvegicusGrm1Galpha(q)-specific metabotropic glutamate GPCRsGeneric receptor
mGluR1GPCR
5Rattus norvegicusNos1nNOSGeneric enzyme
1Mus musculusGsta1Gsta1 (mouse)Generic enzyme
2Mus musculusH2-D1HLA-BGeneric receptor
MHC class IGeneric receptor
3Mus musculusH2-EaHLA-DRA1Generic receptor
MHC class IIGeneric receptor
MHC class II alpha chainGeneric receptor
4Mus musculusH2-EaHLA-DRA1Generic receptor
MHC class IIGeneric receptor
MHC class II alpha chainGeneric receptor
5Mus musculusH2-LH-2 L(d)Generic receptor
HLA-CGeneric receptor
MHC class IGeneric receptor
6Mus musculusNos2iNOSGeneric enzyme
7Mus musculusOTTMUSG00000015050Trav9d-4Generic receptor
8Mus musculusPolmDNA polymerase muGeneric enzyme
9Mus musculusTpmtThiopurine S-methyltransferaseGeneric enzyme
10Mus musculusUap1UAP1Generic enzyme
Figure 2

GeneGo Diseases (by Biomarkers) of human, rat and mouse. Sorting is done for the “Statistically significant Diseases” set.

The Network objects and its functions GeneGo Diseases (by Biomarkers) of human, rat and mouse. Sorting is done for the “Statistically significant Diseases” set. Top scored pathway maps were sorted by statistically significant Maps (Figure 3). The top scored pathway maps were immune response alternative complement pathway, G-protein signaling_RhoB regulation pathway and immune response antiviral actions of interferons, respectively. Experimental data from all files is linked to and visualized on the maps as thermometer-like figures. Up-ward thermometers have red color and indicate up-regulated signals and down-ward (blue) ones indicate down-regulated expression levels of the genes.
Figure 3

GeneGo Pathway Maps. Sorting is done for the “Statistically significant Maps” set.

GeneGo Pathway Maps. Sorting is done for the “Statistically significant Maps” set. Complement system can protect the host from microorganisms [25], and the alternative pathway can be directly activated by invading microorganisms. C3/C5 convertases which are complex enzymes transiently assembled on the surface of biological organisms upon activation of the complement system [26]. The generation of active C3/C5 convertases help opsonize, kill, and clear bacteria, parasites and pathogens by eliciting cellular functions including phagocytosis and inflammation [27]. In the map of human, it is initiated by the spontaneous hydrolysis of C3 which is a major effector of humoral branch of the complement system. The down-regulation of C3 treated by dioscin contributes to the down-regulation of C3a and C3b, and then they induce the down-regulation of C5 convertase. For the linkage effect, the cleavage fragments binding to specific receptors suffer affection, including CR1, C3aR, alpha-M/beta-2 integrin, alpha-X/beta-2 intetrin and CD21. In the map of RhoB regulation pathway, RhoB is a member of small GTPases family and can control multiple cellular processes, including actin and microtubule dynamics, gene expression, cell cycle, cell polarity and membrane transport. Their abilities are bound to numerous downstream effectors which lead to diverse parallel downstream signaling pathways [28]. There are several classes of regulatory proteins affect the activation of RhoB. Among them, GGTase-I (Geranylgeranyltrans-ferase type I) and FTase (Farnesyltransferase CAAX box) promote post-translational modification of RhoB (Ras homolog gene family, member A) protein by geranylgeranylation and farnesylation, which are essential for the biological activity of RhoB. In the prediction, down-regulated expression of RhoB gene was induced by down-regulations of GGTase-I and FTase treated with dioscin. In the map of immune response antiviral actions of interferons, iNOS (inducible NO synthase) was the network object. iNOS generates copious amounts of NO presumably to help kill or inhibit the growth of invading microorganisms or neoplastic tissue [29]. Over-expression of iNOS, a common phenomenon during chronic inflammatory conditions, generates sustainable amounts of NO. Its reactive intermediates are mutagenic, causing DNA damage or impairment of DNA repair. Recent studies also implicated NO as a key signaling molecule which can regulate the processes of tumorigenesis. Increased expression of iNOS is involved in tumors of the colon, lung, oropharynx, reproductive organs, breast, and CNS (Central Nervous System) [30]. Thus, the map indicated that dioscin can down regulate the expression level of iNOS gene. Namely, it may be a selective inhibitor of iNOS for chemoprevention of cancer.

GeneGo process networks and Go processes

In the GeneGo process networks analysis, sorting is done for the ‘Statistically significant Networks’ set. There are about 110 cellular and molecular processes whose content is defined and annotated by GeneGo. According to the experimental data (Table 3), ten processes networks with lower p-value were obtain (Table 4). In Go processes, the original Gene Ontology (GO) cellular processes, represented at GeneGo were included. Since most of GO processes have no gene/protein content, the “empty terms” are excluded from p-value calculations, and ten processes with lower p-values were obtain (Table 4). The results are all consistent with GeneGo pathway maps, they were associated with immune response, inflammation and cell cycle signaling, the Go processes include regulation of immune response, DNA replication, RNA transport, protein amino acid famesylation, and regulation of cell killing etc. . GeneGo Diseases (by Biomarkers).
Table 4

Ten GeneGo process networks and Go processes with lower p-values

GeneGo process network
Network Objects Name p-value
Human51Development_Hemopoiesis, Erythropoietin pathway0.000003178
Inflammation_Complement system0.00002487
Cell cycle_G2-M0.00004606
Signal transduction_WNT signaling0.0001901
Signal Transduction_TGF-beta, GDF and Activin signaling0.0007943
Cell cycle_G1-S0.001089
Cell cycle_Meiosis0.00169
Cell cycle_G1-S Growth factor regulation0.00215
Muscle contraction_Nitric oxide signaling in the cardiovascular system0.00228
Protein folding_Folding in normal condition0.002583
Rat7Neurophysiological process_Transmission of nerve impulse0.0005214
Signal Transduction_TGF-beta, GDF and Activin signaling0.006777
Reproduction_GnRH signaling pathway0.008233
Development_Neurogenesis: Synaptogenesis0.009411
Cell adhesion_Synaptic contact0.009819
Reproduction_Gonadotropins regulation0.01165
Neurophysiological process_Taste signaling0.02996
Cell cycle_G0-G10.05999
Neurophysiological process_Circadian rhythm0.0641
Neurophysiological process_Long-term potentiation0.06901
Mouse11Immune_Antigen presentation0.0002078
Immune_Phagosome in antigen presentation0.0004253
Immune_Innate immune response to RNA viral infection0.001665
Inflammation_NK cell cytotoxicity0.00532
Muscle contraction_Relaxin signaling0.05991
Transport_Iron transport0.06608
Immune_Th17-derived cytokines0.06881
Inflammation_IFN-gamma signaling0.07697
Inflammation_Interferon signaling0.07697
Muscle contraction_Nitric oxide signaling in the cardiovascular system0.08035
Go processes
Network ObjectsNamepValue
Human51DNA replication9.331E-09
protein localization in nucleus6.994E-08
mRNA transport1.706E-07
protein amino acid farnesylation1.928E-07
positive regulation of biological process2.181E-07
establishment of RNA localization2.994E-07
nucleic acid transport2.994E-07
RNA transport2.994E-07
RNA localization0.000000357
protein farnesylation3.848E-07
Rat7protein amino acid farnesylation4.46E-10
protein farnesylation8.918E-10
positive regulation of nitric-oxide synthase 2 biosynthetic process1.56E-09
regulation of nitric-oxide synthase 2 biosynthetic process2.496E-09
protein amino acid prenylation9.799E-09
protein prenylation1.274E-08
regulation of sensory perception of pain1.455E-07
regulation of sensory perception1.455E-07
synaptic transmission3.092E-07
transmission of nerve impulse6.724E-07
Mouse11antigen processing and presentation of exogenous peptide antigen4.316E-11
antigen processing and presentation of exogenous antigen9.457E-11
antigen processing and presentation of peptide antigen2.176E-10
antigen processing and presentation4.237E-09
regulation of immune response1.693E-08
positive regulation of leukocyte mediated cytotoxicity1.706E-08
positive regulation of cell killing2.148E-08
positive regulation of immune system process2.238E-08
regulation of leukocyte mediated cytotoxicity4.251E-08
regulation of cell killing5.109E-08
Ten GeneGo process networks and Go processes with lower p-values MetaCore can be used for uploading experimental data (Table 3) to discover and validate biomarker. Using bioinformatics approaches, numerous candidate biomarkers associated with the development or prognosis of human disease were reported. Disease folders represent over 500 human diseases with gene content annotated by GeneGo. Disease folders are organized into a hierarchical tree. In the paper, the enriched disease was detected by the biomarkers. Using network objects known (Table 3) to be associated with dioscin as set of interest, the frequency was recomputed by summing object occurrences for disease. Then, p-values were obtained, which assumes that the probability of picking a network objects annotated with a disease in the reference set. The results are shown in Figure 4. Gene contents may be different greatly between two complex diseases such as cancers and Mendelian diseases. Also, coverages of different diseases in literature are skewed. The two factors may affect p-value prioritization.
Figure 4

The top scored map (map with the lowest p-value) of human, rat and mouse based on the enrichment distribution sorted by ‘Statistically significant Maps’ set. Experimental data from all files is linked to and visualized on the maos as thermometer-like figures. Up-ward thermometers have red color and indicate up-regulated signals and down-ward (blue) ones indicate down regulated expression levels of genes.

The top scored map (map with the lowest p-value) of human, rat and mouse based on the enrichment distribution sorted by ‘Statistically significant Maps’ set. Experimental data from all files is linked to and visualized on the maos as thermometer-like figures. Up-ward thermometers have red color and indicate up-regulated signals and down-ward (blue) ones indicate down regulated expression levels of genes. For human, dioscin may associate itself with experimental autoimmune encephalomyelitis, experimental nervous system autoimmune disease, hypertrophic cicatrix, cicatrix, hemolytic-uremic syndrome, complex and mixed neoplasms, uremia, toxic hepatitis, drug-induced chronic hepatitis, brain ischemia. For rat, dioscin may associate itself with temporal lobe epilepsy, partial epilepsies, amyotrophic lateral sclerosis, melanoma, motor neuron disease, nevi and melanomas, spinal cord diseases, neuroendocrine tumors, hamartoma and epilepsy. For mouse, dioscin may associate itself with ankylosing spondylitis, ulcerative colitis, spondylitis, ankylosis, infectious bone diseases, colitis, spondylarthropathies, spondylarthritis, autoimmune hepatitis, spinal diseases.

The most relevant networks

The network analysis can provide primary information about physical connectivity and functional relationships between proteins/genes. MetaCore database is suitability for manually curated interactions database over 90% human proteins with known function [31]. MetaCore has four “Analyze” network algorithms which are useful when we have a large number of network objects. Among them, analyze network creates a large network and breaks it up into smaller sub-networks which are all ranked by p-value. And analyze transcription regulation works in a similar way. The other two “Analyze” network algorithms (transcription factors and receptors) focus on the presence of either start-nodes or end-nodes of a certain pathway. In the paper, the biological networks were created by Analyze networks algorithm, and the related objects used for network building are listed in Table 3. As all objects on the networks are annotated, they can be associated with one or more cellular functions including DNA repair, cell cycle or apoptosis. The networks can be scored and prioritized based on statistical “relevance” in the function processes and maps. Each network is associated with a g-score and p-value. The priority can be defined as a proportion of the nodes with the data to the total number of nodes on the networks measured with z-score value. In general, a high positive g-score means it is highly saturated with genes from the experiment data. The g-score, p-values and z-score of networks are listed in Table 5, and the top two networks of each species are shown in Figure 5. Relative intensity corresponds to the expression value. Unregulated genes are marked with red circles, while down regulated genes with blue circles. The ‘checkerboard’ color indicates mixed expression for the gene between files or between multiple tags for the same gene.
Table 5

g-score, z-score and p-value of the most relevant networks

No Process Size Target p-value z-score g-score
Human
1mRNA metabolic process (19.5%),50164.35e-3980.5993.09
RNA metabolic process (29.3%),
response to chemical stimulus (41.5%)
2cell division (40.0%),5091.72e-2155.7955.79
mitosis (35.0%),
nuclear division(35.0%)
3glycogen metabolic process (23.1%),5092.39e-2154.9054.90
cellular glucan metabolic process (23.1%),
glucan metabolic process (23.1%)
4intracellular signaling cascade (51.3%),50112.32e-2250.8452.09
signal transduction (71.8%),
biological regulation (97.4%)
5DNA metabolic process (40.5%),5091.15e-1945.2551.50
cellular response to DNA damage stimulus (31.0%),
response to DNA damage stimulus (31.0%)
Rat
1peptidyl-cysteine S-nitrosylation (100.0%),712.54e-0462.6862.68
drug catabolic process (100.0%),
exogenous drug catabolic process (100.0%)
2regulation of metal ion transport (26.5%),5031.78e-0839.5939.59
regulation of ion transport (26.5%),
negative regulation of potassium ion transport (14.7%)
3No processes found401.00e + 000.000.00
Mouse
1N-acetylglucosamine biosynthetic process (100.0%),311.82e-0474.1774.17
UDP-N-acetylglucosamine biosynthetic process (100.0%),
glucosamine biosynthetic process (100.0%)
2positive regulation of immune system process (44.8%),5051.42e-1464.5165.76
regulation of immune system process (51.7%),
regulation of response to stimulus (51.7%)
3positive regulation of Schwann cell differentiation (50.0%),1615.45e-0442.8142.81
regulation of Schwann cell differentiation (50.0%),
response to cobalamin (50.0%)
4response to other organism (100.0%),519.08e-0433.1533.15
response to biotic stimulus (100.0%),
5transepithelial chloride transport (33.3%),911.09e-0330.2630.26
transepithelial transport (33.3%),
somatic hypermutation of immunoglobulin genes (33.3%)
Figure 5

The top two networks scored by MetaCore (AN network) of human (A and B), rat (C and D) and mouse (E and F). A: mRNA metabolic process, RNA metabolic process and response to chemical stimulus of human; B: cell division, mitosis and nuclear division; C: peptidyl-cysteine S-nitrosylation, drug catabolic process and exogenous drug catabolic process; D: regulation of metal ion transport, ion transport and negative regulation of potassium ion transport; E: N-acetylglucosamine biosynthetic, UDP-N-acetylglucosamine biosynthetic and glucosamine biosynthetic process; F: positive regulation of immune system, regulation of immune system and response to stimulus. Thick cyan lines indicate the fragments of canonical pathways. Upregulated genes are marked with red circles; downregulated with blue circles. The ‘checkerboard’ color indicates mixed expression for the gene between files or between multiple tags for the same gene.

g-score, z-score and p-value of the most relevant networks The top two networks scored by MetaCore (AN network) of human (A and B), rat (C and D) and mouse (E and F). A: mRNA metabolic process, RNA metabolic process and response to chemical stimulus of human; B: cell division, mitosis and nuclear division; C: peptidyl-cysteine S-nitrosylation, drug catabolic process and exogenous drug catabolic process; D: regulation of metal ion transport, ion transport and negative regulation of potassium ion transport; E: N-acetylglucosamine biosynthetic, UDP-N-acetylglucosamine biosynthetic and glucosamine biosynthetic process; F: positive regulation of immune system, regulation of immune system and response to stimulus. Thick cyan lines indicate the fragments of canonical pathways. Upregulated genes are marked with red circles; downregulated with blue circles. The ‘checkerboard’ color indicates mixed expression for the gene between files or between multiple tags for the same gene. The network (p=4.35e-39, g-score=93.09) resulting from the experiment data is shown in Figure 5A. The c-Myc is divergence hub, and the ESR1 (nuclear) is a convergence hub in the network. The c-Myc protein is a key transcriptional factor, and it is almost universally involved in cell cycle progression, transformation and apoptosis through targeting of downstream genes [32]. ESR1 (Arabidopsis Enhancer of Shoot Regeneration 1) was identified as a gene that enhance the in vitro shoot regeneration efficiency when over-expressed [33]. The network includes 16 possible targets including ARL5, TOP1, HBB, KNSL1, CBP80, CBP20, Calcineurin B, RENT1, SNRPA, CSTA1, CES1, C3, EGFR, EGF, Alphal-globin and PDESA. EGF is a metastatic inducer of tumor cells, which activates epidermal growth factor receptor (EGFR)-induced signal pathway to induce cancer metastasis [34]. CES1 is the most versatile human carboxylesterase, and it plays critical roles in drug metabolism and lipid mobilization. Excessive induction of CES1 provides a mechanism for potential anti-oxidants protective effect on human health [35]. The cap-binding protein heterodimer CBP80-CBP20 initially undergo a pioneer round of translation of newly synthesixed messenger ribonucleoproteins (mRNPs) [36]. C3 is a main complement in complement pathway [37]. TOP1 unwinds DNA by making transient single strand breaks that relieves the tosion of supercoiled DNA. The network (p=41.72e−21, g-score=55.79) is shown in Figure 5B, which contains 9 of drug targets, including Cyclin A, Cyclin A2, HBB, C3a, TOP1, KNSL1, NUP98, TK1 and FBSW7. The divergence hub of the network was c-Jun, and the convergence hubs were c-Jun, APC/Hcdh1 complex and dTMP cytoplasm. The c-Jun N-terminal kinase (JNK) signaling pathway plays a critical role in inflammation _ complement system [38]. JNK can be activated by exposure of cells to cytokines or environmental stress, indicating that this signaling pathway may contribute to inflammatory responses [39]. And genetic and biochemical studies demonstrate that this signaling pathway also regulates cellular proliferation, apoptosis and tissue morphogenesis [40]. The networks of rat are shown in Figure 5C and D, and the networks of mouse are shown in Figure 5E and F. From the networks, well connected clusters of root nodes were found, and more flexibility in the connection were presented. In Figure 5C, mitomycin C can treat a variety of malignancies, such as head and neck cancers and superficial transitional cell carcinoma of the bladder [41]. The nNOS and mitomycin C is involved in a signal pathway, nNOS is down regulated by dioscin while mitomycin C is up-regulation. Thus, dioscin could be used to anti-cancer through that pathway. In Figure 5E, N-acetylglucosamine-1-phosphate catalyzes the formation of UDP-GlcNAC, which is an essential precursor of petidoglycan and the rhamnose-GlcNAc linker region of mycobacterial cell wall [42]. Thus, dioscin may be a potential anti-infections drug through down-regulation of UAP1. All those results indicated that dioscin may exert biological effects through multi-channel. Such as, dioscin is a TOP1 inhibitor, inhibits relegation and stabilizes the DNA-TOP1 complex in the cleaved DNA form, ultimately leading to breaks of DNA chains and cell death. Thus, the dioscin could used to treat cancer though the cell cycle–transition and termination of DNA replication pathway. And it could inhibit cancer metastasis through EGFR-induced signal pathway. In addition, it could be used to treat inflammation though JNK signaling pathway. However, the dioscin may induce some side effect by down-regulation of complement system.

Conclusions

In the paper, we presented an application of in-silico inverse docking technique coupled with bioinformatics approach to predict the possible targets, biological activities, signal pathways and regulating networks of dioscin. Those studies provide valuable information for future in vitro and in vivo works to validate the previous in silico findings.

Availability and supporting data

MetaCore is available at http://www.genego.com.
  42 in total

Review 1.  Mammalian nitric oxide synthases.

Authors:  D J Stuehr
Journal:  Biochim Biophys Acta       Date:  1999-05-05

Review 2.  Which came first, the lectin/classical pathway or the alternative pathway of complement?

Authors:  Alister W Dodds
Journal:  Immunobiology       Date:  2002-09       Impact factor: 3.144

3.  Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays.

Authors:  Stephen J Haggarty; Kathryn M Koeller; Jason C Wong; Rebecca A Butcher; Stuart L Schreiber
Journal:  Chem Biol       Date:  2003-05

Review 4.  Bioinformatics and cancer target discovery.

Authors:  Brian Desany; Zemin Zhang
Journal:  Drug Discov Today       Date:  2004-09-15       Impact factor: 7.851

5.  Antioxidant sulforaphane and sensitizer trinitrobenzene sulfonate induce carboxylesterase-1 through a novel element transactivated by nuclear factor-E2 related factor-2.

Authors:  Yi-Tzai Chen; Deshi Shi; Dongfang Yang; Bingfang Yan
Journal:  Biochem Pharmacol       Date:  2012-07-06       Impact factor: 5.858

Review 6.  Control of the complement system.

Authors:  M K Liszewski; T C Farries; D M Lublin; I A Rooney; J P Atkinson
Journal:  Adv Immunol       Date:  1996       Impact factor: 3.543

7.  A fast flexible docking method using an incremental construction algorithm.

Authors:  M Rarey; B Kramer; T Lengauer; G Klebe
Journal:  J Mol Biol       Date:  1996-08-23       Impact factor: 5.469

8.  Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB.

Authors:  P F Lebowitz; P J Casey; G C Prendergast; J A Thissen
Journal:  J Biol Chem       Date:  1997-06-20       Impact factor: 5.157

9.  The conversion of human complement component C5 into fragment C5b by the alternative-pathway C5 convertase.

Authors:  R G DiScipio
Journal:  Biochem J       Date:  1981-12-01       Impact factor: 3.857

10.  Transcriptional regulation of the ornithine decarboxylase gene by c-Myc/Max/Mad network and retinoblastoma protein interacting with c-Myc.

Authors:  Merja Auvinen; Kristiina Järvinen; Anneli Hotti; Juha Okkeri; Jens Laitinen; Olli A Jänne; Philip Coffino; Mathias Bergman; Leif C Andersson; Kari Alitalo; Erkki Hölttä
Journal:  Int J Biochem Cell Biol       Date:  2003-04       Impact factor: 5.085

View more
  5 in total

1.  Mechanism of action involved in the anxiolytic-like effects of Hibalactone isolated from Hydrocotyle umbellata L.

Authors:  Matheus Gabriel de Oliveira; Lorrane Kelle da Silva Moreira; Larissa Cordova Turones; Dionys de Souza Almeida; Aline Nazareth Martins; Thiago Levi Silva Oliveira; Vinicius Barreto da Silva; Leonardo Luiz Borges; Elson Alves Costa; José Realino de Paula
Journal:  J Tradit Complement Med       Date:  2021-09-11

2.  Compounds Identified from Marine Mangrove Plant (Avicennia alba) as Potential Antiviral Drug Candidates Against WDSV, an In-Silico Approach.

Authors:  Mohammed Othman Aljahdali; Mohammad Habibur Rahman Molla; Foysal Ahammad
Journal:  Mar Drugs       Date:  2021-04-28       Impact factor: 5.118

Review 3.  Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy: New Insights.

Authors:  Saeid Shahrabi; Abbas Khosravi; Mohammad Shahjahani; Fakher Rahim; Najmaldin Saki
Journal:  Oncol Rev       Date:  2016-12-14

Review 4.  Reverse Screening Methods to Search for the Protein Targets of Chemopreventive Compounds.

Authors:  Hongbin Huang; Guigui Zhang; Yuquan Zhou; Chenru Lin; Suling Chen; Yutong Lin; Shangkang Mai; Zunnan Huang
Journal:  Front Chem       Date:  2018-05-09       Impact factor: 5.221

Review 5.  Techniques and Strategies for Potential Protein Target Discovery and Active Pharmaceutical Molecule Screening in a Pandemic.

Authors:  Hongxin Yu; Chunyan Li; Xing Wang; Jingyi Duan; Na Yang; Lijuan Xie; Yu Yuan; Shanze Li; Chenghao Bi; Bin Yang; Yubo Li
Journal:  J Proteome Res       Date:  2020-10-04       Impact factor: 4.466

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.